Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 6/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31362927 | 0.83 | HTR2C (0.32) | PSMB1PSMB5HTR2CHDAC3HDAC1 | |
| SCHEMBL31389005 | 0.82 | PSMB1 (0.40) | PSMB1PSMB5PSMB2TNFHTR2A | |
| SCHEMBL31362912 | 0.77 | HTR2C (0.42) | PSMB1PSMB5HTR2AHTR2C | |
| SCHEMBL25324896 | 0.74 | PSMB1 (0.41) | PSMB1PSMB5PSMB2TNFHDAC3 | |
| SCHEMBL31362923 | 0.74 | PSMB1 (0.38) | PSMB1PSMB5PSMB2TNFHTR2A | |
| SCHEMBL31388996 | 0.74 | PSMB1 (0.35) | PSMB1PSMB5HTR2CHDAC3HDAC1 | |
| SCHEMBL31362889 | 0.73 | AAK1 (0.37) | PSMB1PSMB5PSMB2 | |
| SCHEMBL25320684 | 0.72 | HTR2C (0.36) | PSMB1PSMB5HTR2AHTR2C | |
| SCHEMBL25320682 | 0.72 | HTR2C (0.36) | PSMB1PSMB5HTR2AHTR2C | |
| SCHEMBL30550753 | 0.72 | HTR2C (0.36) | PSMB1PSMB5HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066328-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066328-A1 | PARP7 INHIBITORS | PARP1, PARP2, PARP8 | PSMB1 1697/4885PSMB5 1775/4885PSMB2 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.